Induction Docetaxel, Cisplatin, and Cetuximab Followed by Concurrent Radiotherapy, Cisplatin, and Cetuximab and Maintenance Cetuximab in Patients With Locally Advanced Head and Neck Cancer

PURPOSE: We incorporated cetuximab, a chimeric monoclonal antibody against the epidermal growth factor receptor (EGFR), into the induction therapy and subsequent chemoradiotherapy of head and neck cancer (HNC). PATIENTS AND METHODS: Patients with locally advanced HNC, including squamous and undiffer...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Argiris, Athanassios, Heron, Dwight E., Smith, Ryan P., Kim, Seungwon, Gibson, Michael K., Lai, Stephen Y., Branstetter, Barton F., Posluszny, Donna M., Wang, Lin, Seethala, Raja R., Dacic, Sanja, Gooding, William, Grandis, Jennifer R., Johnson, Jonas T., Ferris, Robert L.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2010
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3018361/
https://ncbi.nlm.nih.gov/pubmed/21079141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.30.6423
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars